SIRT1 and hepatocellular carcinoma: SIRT1 activators have demonstrated therapeutic potential in mitigating fibrosis, reducing oxidative stress, and preventing liver injury, while SIRT1 inhibitors show promise in cancer therapy by inducing apoptosis in HCC.